Preclinical Data Support Potential Combinations for Allovectin(R) With Emerging Immunotherapies

[at noodls] – SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced the release of animal data at a melanoma conference documenting the benefits of combining the company’s Allovectin® … more

View todays social media effects on VICL

View the latest stocks trending across Twitter. Click to view dashboard